股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 山東博安生物技術股份有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06955 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | 本月底法定/註冊股本總額： RMB 622,333,694 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 – 1 – | 現行章程 | | | | | | | 建議修訂 | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 在上述首次境外發行上市及非境外上 | | | | | | | | | | | | | | 在上述首次境外發行上市及非境外上 | | | | | | | | | | 市股份轉換為H股全部完成後，公司的 | | | | | | | | | | | | | | 市股份轉換為H股全部完成後，公司的 | | | | | | | | | | 股509,27 ...

山東博安生物技術股份有限公司 章 程 山東博安生物技術股份有限公司 第五條 公 司 的 法 定 代 表 人 由 執 行 公 司 事 務 的 董 事 或 經 理 擔 任。 擔 任 法 定 代 表 人 的 董 事 或 者 經 理 辭 任 的，視 為 同 時 辭 去 法 定 代 表 人。 | 第一章 | | 總則 | | 3 | | --- | --- | --- | --- | --- | | 第二章 | | 經營宗旨和範圍 | | 5 | | 第三章 | | 股份 | | 5 | | 第一節 | | 股份發行 | | 5 | | 第二節 | | 股份增減和回購 | | 9 | | 第三節 | | 股份轉讓 | | 10 | | 第四節 | | 股票和股東名冊 | | 11 | | 第四章 | | 股東和股東會 | | 13 | | 第一節 | 股東 | | | 13 | | 第二節 | | 股東會的一般規定 | | 16 | | 第三節 | 股東會的召集 | | | 19 | | 第四節 | | 股東會的提案與通知 | | 21 | | 第五節 | 股東會的召開 | | | 23 | | 第六節 | | 股東會 ...

山東 博 安 生 物 技 術 股 份 有限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 股份代號 : 6955 2025 中期報告 目錄 2 公司概覽 3 公司資料 5 財務摘要 6 管理層討論及分析 26 其他資料 30 獨立審閱報告 31 中期簡明綜合損益及其他全面收益表 32 中期簡明綜合財務狀況表 34 中期簡明綜合權益變動表 35 中期簡明綜合現金流量表 37 中期簡明綜合財務資料附註 公司概覽 山東博安生物技術股份有限公司（「博安生物」或「本公司」，連同其附屬公司統稱「本集團」）成立於2013年，是一家 綜合性生物製藥公司，專門從事生物製品的研發、生產及營銷，專注於腫瘤、自身免疫性疾病、眼科及代謝疾病 等治療領域。本公司圍繞多個平台開展藥物發現活動：全人抗體轉基因小鼠及噬菌體展示技術平台、雙特異T-cell Engager技術平台、ADC技術平台及細胞治療平台。 博安生物的業務覆蓋全產業鏈，涵蓋抗體發現、細胞株開發、上游及下游工藝開發、分析及生物分析方法開發、技 術轉移、非臨床研究、臨床研究、法規及註冊以及商業化規模生產。在細胞治療領域，博安生物專注 ...

Core Viewpoint - The stock of Boan Biotechnology (06955) has seen a significant increase of over 14%, currently trading at 14.36 HKD with a transaction volume of 290 million HKD, indicating strong market interest and confidence in the company's future prospects [1] Financial Performance - Boan Biotechnology has effectively controlled expenses in the first half of the year, although the launch of the new product, Dexamethasone, has led to a temporary decrease in gross margin [1] - The company has experienced a dynamic reduction in R&D expense ratio while maintaining reasonable fluctuations in sales expense ratio, indicating efficient cost management [1] - The company currently has ample cash reserves, which supports the rapid advancement of its innovative drug pipeline [1] Technological Capabilities - Boan Biotechnology has established four major technology platforms: fully human antibody transgenic mouse platform, bispecific TCE technology platform, ADC technology platform, and AI application platform, positioning itself for next-generation IO+ADC therapies [1] - The fully human antibody transgenic mouse platform includes 30 human antibody kappa light chain variable region genes and 110 human antibody heavy chain variable region genes (IgM and IgG1), enabling rapid immune response and high antibody titers, validated across numerous antibody projects [1] - The ADC platform is continuously upgraded, focusing on differentiated toxins and indications, including CLDN18.2 ADC, CD228 ADC, next-generation bispecific ADC, and bispecific toxin ADC [1] Market Potential - Huazhong Securities expresses optimism regarding the comprehensive capabilities of the company's biopharmaceutical platform and the significant market potential of its FIC innovative pipeline [1]

Group 1 - The stock of Boan Biotechnology (06955.HK) increased by over 14% on September 16, reaching a price of 14.36 HKD [1] - As of the report, the stock was up 10.46% with a trading volume of 290 million HKD [1]

Core Viewpoint - The stock of Bohan Biotech (06955) has seen a significant increase of over 14%, currently trading at 14.36 HKD with a transaction volume of 290 million HKD, indicating strong market interest and confidence in the company's future prospects [1] Financial Performance - In the first half of the year, Bohan Biotech effectively controlled expenses, although the launch of the new product, Dexamethasone, led to a temporary decrease in gross margin [1] - The company has experienced a dynamic reduction in R&D expense ratio while maintaining reasonable fluctuations in sales expense ratio [1] - Bohan Biotech currently has ample cash reserves, which supports the rapid advancement of its innovative drug pipeline [1] Technological Capabilities - The company has established four major technology platforms: fully human antibody transgenic mouse platform, bispecific TCE technology platform, ADC technology platform, and AI application platform, positioning itself for next-generation IO+ADC therapies [1] - The BA-huMab fully human antibody transgenic mouse platform includes 30 human antibody kappa light chain variable region genes and 110 human antibody heavy chain variable region genes (IgM and IgG1), enabling rapid immune response and high antibody titers [1] - The ADC platform is continuously upgraded, featuring differentiated toxins and indications, including CLDN18.2 ADC, CD228 ADC, next-generation bispecific ADC, and bispecific toxin ADC [1] Market Potential - Huazhong Securities expresses optimism regarding the company's biopharmaceutical platform's comprehensive capabilities and the significant market potential of its FIC innovative pipeline [1]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 山東博安生物技術股份有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06955 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 574,333,694 | RMB | 1 | RMB | | 574,333,694 | | 增加 / 減少 (-) | | | 48,000,000 | | | RMB | | 48,000,000 | | 本月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | 本月底法定/註冊股 ...

Group 1 - The Hang Seng Index closed down 0.66% and the Hang Seng Tech Index fell by 1.04% on August 28 [1] - Jiaxin International Resources surged over 130% on its first day of trading [1] - Semiconductor Manufacturing International Corporation (SMIC) rose over 8%, while ZTE Corporation increased by over 6% [1] Group 2 - Both Boan Biological and Aikang Medical experienced declines of over 12% [1]